{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:40:26Z","timestamp":1791380426262,"version":"4.3.3"},"reference-count":55,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objectives\nThe aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (FAs) and inositol alone and in combination for the treatment of pediatric bipolar (BP) spectrum disorder in young children.\nMethods\nParticipants were male and female children ages 5\u201312 meeting DSM-IV diagnostic criteria for a BP spectrum disorder and displaying mixed, manic, or hypomanic symptoms without psychotic features at the time of evaluation.\nResults\nParticipants concomitantly taking psychotropic medication were excluded from efficacy analyses. There were significant reductions in YMRS and HDRS mean scores in the inositol and combination treatment groups (all p &lt; 0.05) and in CDRS mean scores in the combination treatment group (p &lt; 0.001), with the largest changes seen in the combination group. Those receiving the combination treatment had the highest rates of antimanic and antidepressant response. The odds ratios for the combination group compared to the omega-3 FAs and inositol groups were clinically meaningful (ORs \u22652) for 50% improvement on the YMRS, normalization of the YMRS (score<\/jats:p>","DOI":"10.64719\/pb.4449","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"31-51","source":"Crossref","is-referenced-by-count":4,"title":["A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5\u201312"],"prefix":"10.64719","volume":"52","author":[{"given":"Janet","family":"Wozniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"DiSalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atilla","family":"Ceranoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Vaudreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmaline","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Biederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lewinsohn P, Klein D, Seeley J. Bipolar disorders in a community sample of older adolescents: Prevalence, phenomenology, comorbidity, and course. J Am Child Adolesc Psychiatry. 1995;34(4):454\u2013463.","DOI":"10.1097\/00004583-199504000-00012"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Merikangas KR, He JP, Burstein M et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication\u2014Adolescent Supplement (NCS-A) J Am Acad Child Adolesc Psychiatry. 2010;49(10):980\u2013989.","DOI":"10.1016\/j.jaac.2010.05.017"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Van Meter A, Moreira ALR, Youngstrom E et al. Updated meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2019;80(3):18r12180.","DOI":"10.4088\/JCP.18r12180"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Biederman J, Birmaher B, Carlson GA et al. National Institute of Mental Health Research Roundtable on Prepubertal Bipolar Disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(8):871\u2013878.","DOI":"10.1097\/00004583-200108000-00007"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Joshi G, Wilens T. Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009;18(2):291\u2013319. vii\u2013viii.","DOI":"10.1016\/j.chc.2008.12.005"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Wozniak J, Biederman J, Kiely K et al. Mania-like symptoms suggestive of childhood onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34(7):867\u2013876.","DOI":"10.1097\/00004583-199507000-00010"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Biederman J, Faraone S, Wozniak J, Mick E, Kwon A, Aleardi M. Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: findings from a large sample of clinically referred preadolescent children assessed over the last 7 years. J Affect Disord. 2004;82(Suppl 1):S45\u2013S58.","DOI":"10.1016\/j.jad.2004.05.021"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dickstein DP, Rich BA, Binstock AB et al. Comorbid anxiety in phenotypes of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2005;15(4):534\u2013548.","DOI":"10.1089\/cap.2005.15.534"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Findling RL, Stepanova E, Youngstrom EA et al. Progress in diagnosis and treatment of bipolar disorder among children and adolescents: an international perspective. Evid Based Ment Health. 2018;21:177\u2013181.","DOI":"10.1136\/eb-2018-102912"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liu HY, Potter MP, Woodworth KY et al. Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(8):749\u2013762. e739.","DOI":"10.1016\/j.jaac.2011.05.011"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Konstantakopoulos G, Dimitrakopoulos S, Michalopoulou PG. Drugs under early investigation for the treatment of bipolar disorder. Expert Opin Investig Drugs. 2015;24(4):477\u2013490. doi: 10.1517\/13543784.2015.1019061. doi: Epub 2015 Feb 23. PMID: 25704484.","DOI":"10.1517\/13543784.2015.1019061"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Arnold L Eugene et al. Omega-3 fatty acid plasma levels before and after supplementation: correlations with mood and clinical outcomes in the omega-3 and therapy studies. J Child Adolesc Psychopharmacol. 2017;27(3):223\u2013233. doi: 10.1089\/cap.2016.0123. doi:","DOI":"10.1089\/cap.2016.0123"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit\/hyperactivity disorder symptomatology: systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50(10):991\u20131000.","DOI":"10.1016\/j.jaac.2011.06.008"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Patel NC, DelBello MP, Cecil KM et al. Lithium treatment effects on Myo-inositol in adolescents with bipolar depression. Biol Psychiatry. 2006;60(9):998\u20131004.","DOI":"10.1016\/j.biopsych.2006.07.029"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry. 1989;146(10):1251\u20131260.","DOI":"10.1176\/ajp.146.10.1251"},{"key":"ref16","unstructured":"Belmaker RH, Levine J. Natural Medications for Psychiatry: Considering the Alternatives. 2nd. Philadelphia, USA: Lippincott Williams & Wilkins; 2008. Inositol in the treatment of psychiatric disorders; p. 111. In: Mischoulon D, Rosenbaum JF, eds."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Case KC, Salsaa M, Yu W, Greenberg ML. Regulation of Inositol Biosynthesis: Balancing Health and Pathophysiology. Handb Exp Pharmacol. 2020;259:221\u2013260. doi: 10.1007\/164_2018_181. doi: PMID: 30591968.","DOI":"10.1007\/164_2018_181"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Michell RH. Do inositol supplements enhance phosphatidylinositol supply and thus support endoplasmic reticulum function. Br J Nutr. 2018;120(3):301\u2013316. doi: 10.1017\/S0007114518000946. doi: Epub 2018 Jun 3. PMID: 29859544.","DOI":"10.1017\/S0007114518000946"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Wei H, Landgraf D, Wang G, McCarthy MJ. Inositol polyphosphates contribute to cellular circadian rhythms: implications for understanding lithium\u2019s molecular mechanism. Cell Signal. 2018;44:82\u201391. doi: 10.1016\/j.cellsig.2018.01.001. doi: Epub 2018 Jan 11. PMID: 29331582.","DOI":"10.1016\/j.cellsig.2018.01.001"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59(10):913\u2013919.","DOI":"10.1001\/archpsyc.59.10.913"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477\u2013479.","DOI":"10.1176\/appi.ajp.159.3.477"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006;163(6):1098\u20131100.","DOI":"10.1176\/ajp.2006.163.6.1098"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Arnold LE, Young AS, Belury MA, Cole RM, Gracious B, Seidenfeld AM, Wolfson H, Fristad MA. Omega-3 fatty acid plasma levels before and after supplementation: correlations with mood and clinical outcomes in the omega-3 and therapy studies. J Child Adolesc Psychopharmacol. 2017;27(3):223\u2013233. doi: 10.1089\/cap.2016.0123. doi: Epub 2017 Feb 3. PMID: 28157380; PMCID: PMC5397211.","DOI":"10.1089\/cap.2016.0123"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Fristad MA, Young AS, Vesco AT et al. A randomized controlled trial of individual family psychoeducational psychotherapy and omega-3 fatty acids in youth with subsyndromal bipolar disorder. J Child Adolesc Psychopharmacol. 2015;25(10):764\u2013774. doi: 10.1089\/cap.2015.013. doi:","DOI":"10.1089\/cap.2015.013"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol. 2007;17(6\u20137):440\u2013447.","DOI":"10.1016\/j.euroneuro.2006.11.006"},{"key":"ref26","unstructured":"Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiatry. 1978;13(1):65\u201372."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Davanzo P, Thomas MA, Yue K et al. Decreased anterior cingulate myo-inositol\/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology. 2001;24(4):359\u2013369.","DOI":"10.1016\/S0893-133X(00)00207-4"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014;29(1):55\u201363.","DOI":"10.1002\/hup.2369"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Wozniak J, Faraone SV, Chan J, Tarko L, Hernandez M, Davis J, Woodworth Y, Biederman J. Correction: a randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study. J Clin Psychiatry. J Clin Psychiatry. 2016;2015;7776(9)(11):e1153. 1548\u201355. doi: 10.4088\/JCP.16lcx11151. doi: Erratum for. PMID: 27780327.","DOI":"10.4088\/JCP.16lcx11151"},{"key":"ref30","unstructured":"Orvaschel H, Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School-Age Children: Epidemiologic Version. Fort Lauderdale, FL: Nova University; 1987."},{"key":"ref31","unstructured":"Orvaschel H. Schedule for Affective Disorders and Schizophrenia for School-Age Children Epidemiologic Version. 5th. Ft. Lauderdale: Nova Southeastern University: Center for Psychological Studies; 1994."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429\u2013435.","DOI":"10.1192\/bjp.133.5.429"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gracious BL, Youngstrom EA, Findling RL, Calabrese JR. Discriminative validity of a parent version of the Young Mania Rating Scale. J Am Acad Child Adolesc Psychiatry. 2002;41(11):1350\u20131359.","DOI":"10.1097\/00004583-200211000-00017"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Youngstrom EA, Danielson CK, Findling RL, Gracious BL, Calabrese JR. Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. J Clin Child Adolesc Psychol. 2002;31(4):567\u2013572.","DOI":"10.1207\/S15374424JCCP3104_15"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031\u20131037.","DOI":"10.1001\/archpsyc.1997.01830230069010"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","DOI":"10.1136\/jnnp.23.1.56"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766\u2013771.","DOI":"10.1001\/archpsyc.1976.01770060086012"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"DuPaul GJ, Power TJ, Anastopoulos A, Reed R. The ADHD Rating Scale-IV Checklist, Norms and Clinical Interpretation. New York, NY: Guilford Press; 1998.","DOI":"10.1037\/t00680-000"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lachar D, Bailley SE, Rhoades HM et al. New subscales for an anchored version of the brief psychiatric rating scale: construction, reliability, and validity in acute psychiatric admissions. Psychol Assess. 2001;13:384\u2013395.","DOI":"10.1037\/1040-3590.13.3.384"},{"key":"ref40","unstructured":"National Institute of Mental Health. CGI (Clinical Global Impression) Scale \u2013 NIMH. Psychopharmacol Bull. 1985;21(8):839\u2013844."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Kaufman AS, Kaufman NL. Kaufman Brief Intelligence Test. Second. Bloomington, MN: Pearson, Inc; 2004.","DOI":"10.1037\/t27706-000"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler Adult Intelligence Scale. 4th. San Antonia, TX: Pearson; 2008.","DOI":"10.1037\/t15169-000"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Posner K, Brent D, Lucas C. Columbia-Suicide Severity Rating Scale (C-SSRS) New York, NY: The Research Foundation for Mental Hygene, Inc; 2008.","DOI":"10.1037\/t52667-000"},{"key":"ref44","unstructured":"College Station, TX: StatCorp LLC; 2019. Stata Statistical Software: Release 16 [computer program]"},{"key":"ref45","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. Second. Hillsdale, NJ: Erlbaum; 1988."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, Fan B, Lu C, McIntyre RS. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry. Transl Psychiatry. 2019 2021 Aug 5 7;Sep 5 7;911(1)(1):190. 465. doi: 10.1038\/s41398-019-0515-5. doi: Erratum in. PMID: 31383846; PMCID: PMC6683166.","DOI":"10.1038\/s41398-019-0515-5"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Okereke OI, Vyas CM, Mischoulon D et al. Effect of long-term supplementation with marine omega-3 fatty acids vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2021;326(23):2385\u20132394. doi: 10.1001\/jama.2021.21187. doi:","DOI":"10.1001\/jama.2021.21187"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Chengappa KN, Levine J, Gershon S et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2000;2(1):47\u201355.","DOI":"10.1034\/j.1399-5618.2000.020107.x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Nierenberg AA, Ostacher MJ, Calabrese JR et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210\u2013216.","DOI":"10.1176\/appi.ajp.163.2.210"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Evins EA, Demopulos C, Yovel I et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 2006;8(2):168\u2013174.","DOI":"10.1111\/j.1399-5618.2006.00303.x"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Rucklidge JJ, Gately D, Kaplan BJ. Database analysis of children and adolescents with Bipolar Disorder consuming a micronutrient formula. BMC Psychiatry. 2010;10:74. doi: 10.1186\/1471-244X-10-74.","DOI":"10.1186\/1471-244X-10-74"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Wozniak J, Petty CR, Schreck M, Moses A, Faraone SV, Biederman J. High level of persistence of pediatric bipolar-I disorder from childhood onto adolescent years: a four year prospective longitudinal follow-up study. J Psychiatr Res. 2011;45(10):1273\u20131282.","DOI":"10.1016\/j.jpsychires.2010.10.006"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Wei H, Landgraf D, Wang G, McCarthy MJ. Inositol polyphosphates contribute to cellular circadian rhythms: Implications for understanding lithium\u2019s molecular mechanism. Cell Signal. 2018;44:82\u201391. doi: 10.1016\/j.cellsig.2018.01.001. doi: Epub 2018 Jan 11. PMID: 29331582.","DOI":"10.1016\/j.cellsig.2018.01.001"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Trkulja V, Bari\u0107 H. Current research on complementary and alternative medicine (CAM) in the treatment of major depressive disorder: an evidence-based review. Advances in Experimental Medicine and Biology. 2021;1305:375\u2013427.","DOI":"10.1007\/978-981-33-6044-0_20"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Zhang L, Liu H, Kuang L, Meng H, Zhou X. Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: a meta-analysis of randomized placebo-controlled trials. Child Adolesc Psychiatry Ment Health. 2019;13:36.","DOI":"10.1186\/s13034-019-0296-x"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:31:20Z","timestamp":1791315080000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/a-randomized-double-blind-controlled-clinical-trial-of-omega-3-fatty-acids-and-inositol-as-monotherapies-and-in-combination-for-the-treatment-of-pediatric-bipolar-spectrum-disorder-in-children-age-5\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4449","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}